◆英語タイトル:Norgine BV - Strategic SWOT Analysis Review
◆商品コード:GDPH31841SA
◆発行会社(調査会社):
GlobalData
◆発行日:2020年12月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Norgine BV – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Highlights
Norgine BV (Norgine) develops, manufactures, and commercializes specialty pharmaceuticals and medical devices. The company’s product portfolio spans branded drugs and devices in the areas of gastroenterology, hepatology, and cancer and supportive care. It also advances pipeline candidates for the treatment of various gastroenterological and hepatological diseases and disorders. Norgine serves healthcare systems and patients in Europe, New Zealand, and Australia. Its prominent partners include Takeda, Bausch Health, Abeona Therapeutics, Alfasigma, Amicus, China Medical System Holdings, Modi-Mundipharma, Navidea, Noventure, and Olympus Corp, among others. The company has subsidiaries in the UK, Italy, Germany, Portugal, Switzerland, Austria, France, Belgium, Denmark, Spain, New Zealand, Australia, South Africa, and Egypt. Norgine is headquartered in the Netherlands.
Norgine BV Key Recent Developments
Jun 16,2020: Norgine senior management changes: Christopher Bath appointed Chief Operating Officer
Jun 19,2019: Norgine recognised for excellence in health and safety with RoSPA Gold Medal Award fifth year in a row
Apr 04,2019: Norgine: New study highlights need to increase public understanding of important role of colonoscopy in preventing and diagnosing gastrointestinal diseases, including Colorectal Cancer
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Norgine BV – Key Facts
Norgine BV – Key Employees
Norgine BV – Key Employee Biographies
Norgine BV – Major Products and Services
Norgine BV – History
Norgine BV – Company Statement
Norgine BV – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Norgine BV – Business Description
Business Segment: Net Product Revenue
Performance
R&D Overview
Norgine BV – Corporate Strategy
Norgine BV – SWOT Analysis
SWOT Analysis – Overview
Norgine BV – Strengths
Norgine BV – Weaknesses
Norgine BV – Opportunities
Norgine BV – Threats
Norgine BV – Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Norgine BV, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Norgine BV, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Norgine BV, Recent Deals Summary
Section 4 – Company’s Recent Developments
Jun 16, 2020: Norgine senior management changes: Christopher Bath appointed Chief Operating Officer
Jun 19, 2019: Norgine recognised for excellence in health and safety with RoSPA Gold Medal Award fifth year in a row
Apr 04, 2019: Norgine: New study highlights need to increase public understanding of important role of colonoscopy in preventing and diagnosing gastrointestinal diseases, including Colorectal Cancer
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Norgine BV, Key Facts
Norgine BV, Key Employees
Norgine BV, Key Employee Biographies
Norgine BV, Major Products and Services
Norgine BV, History
Norgine BV, Subsidiaries
Norgine BV, Key Competitors
Norgine BV, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Norgine BV, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Norgine BV, Recent Deals Summary